These authors contributed equally to this study.
Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes
Article first published online: 2 DEC 2004
British Journal of Haematology
Volume 128, Issue 2, pages 204–209, January 2005
How to Cite
Musto, P., Lanza, F., Balleari, E., Grossi, A., Falcone, A., Sanpaolo, G., Bodenizza, C., Scalzulli, P. R., Sala, A. L., Campioni, D., Ghio, R., Cascavilla, N. and Carella, A. M. (2005), Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. British Journal of Haematology, 128: 204–209. doi: 10.1111/j.1365-2141.2004.05288.x
- Issue published online: 2 DEC 2004
- Article first published online: 2 DEC 2004
- Received 17 July 2004; accepted for publication 4 October 2004
- myelodysplastic syndromes;
Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 μg s.c. for at least 12 weeks. Fifteen patients (40·5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7–22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin <100 IU/l, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.